•  
  •  
  •  
  •  

2026-03-27 07:41:52

  • Home
  • Commodities
  • Industry News
  • IPO
  • Mutual Funds
  • Others
  • Research
  • Watch List
Latest News
  • EaseMyTrip Enters Exclusive Partnership with MSTC Ltd. to Power Travel Services for Govt Sector
  • Sundaram-Clayton Completes Rs 558.62 Cr Land Sale
  • 3i Infotech Digital BPS Ltd receives order from Mahanagar Gas Ltd
  • AZAD Engineering Ltd signs long term contract with Mitsubishi Heavy Industries Ltd
  • PNGS Gargi Fashion Jewellery Ltd opens new store in Pune

Keywords Selected:  Biosimilar

Stock Report

  • CuraTeQ Biologics Pvt Ltd enters into agreement with STADA Arzneimittel AG
  • Zydus Lifesciences announces successful clinical development of Pembrolizumab biosimilar FYB206, marking a milestone toward USFDA filing
  • Lupin receives European Commission approval for Biosimilar Ranibizumab
  • Zydus launches biosimilar Aflibercept 2 mg ANYRA™ for advancing ophthalmic care
  • CuraTeQ Biologics Pvt Ltd and BioFactura Inc, USA to terminate agreement mutually
  • Biocon Biologics Secures Full Global Rights to Biosimilar Adalimumab through Expanded FKB In-Licensing Agreement
  • Lupin receives Positive CHMP Opinion for Biosimilar Ranibizumab
  • Biocon Biologics Signs Settlement and License Agreement to Commercialize Biosimilar Aflibercept Worldwide
  • Zydus launches biosimilar Denosumab 120 mg SC - protecting bone health in cancer patients
  • Lupin and Valorum Enter into an Exclusive Licensing Agreement for Biosimilar Armlupeg™ in the United States
  • Lupin Receives Approval from U.S. FDA for Biosimilar Armlupeg - Pegfilgrastim-unne
  • Biocon Biologics Receives Health Canada Approval for Yesintek™ and Yesintek™ I.V., a Biosimilar to Stelara®
  • Biocon Biologics Secures U.S. Market Entry Date for Bosaya™ and Aukelso™, Denosumab Biosimilars
  • CuraTeQ Biologics Pvt Ltd completes Phase 3 Clinical Study for Denosumab Biosimilar
  • CuraTeQ Biologics receives approval for biosimilar Dazublys from UK's MHRA
  • Lupin announces licensing deal for Ranibizumab Biosimilar
  • Lupin and Zentiva Sign License and Supply Agreement for Commercializing Certolizumab
  • Lupin Ltd enters into agreement with Zentiva for biosimilar Certolizumab Pegol
  • Biocon Biologics Collaborates with National Cancer Society Malaysia
  • OneSource and Xbrane Biopharma Announce Biosimilars Manufacturing Partnership for the Global Markets
  • Biocon Biologics Receives Positive CHMP Opinions for Biosimilar Denosumab in Europe
  • CuraTeQ Biologics receives positive opinion for biosimilar Dazublys® from EMA
  • Biocon Biologics secures Market Entry Date for Yesafili™, an Interchangeable Biosimilar to Eylea®, in the U.S.
  • Biocon Biologics announces U.S. FDA Approval for Jobevne™, Biosimilar Bevacizumab, Expanding Its Oncology Portfolio

Latest Post

  • EaseMyTrip Enters Exclusive Partnership with MSTC Ltd. to Power Travel Services for Govt Sector
  • Sundaram-Clayton Completes Rs 558.62 Cr Land Sale
  • 3i Infotech Digital BPS Ltd receives order from Mahanagar Gas Ltd
  • AZAD Engineering Ltd signs long term contract with Mitsubishi Heavy Industries Ltd
  • PNGS Gargi Fashion Jewellery Ltd opens new store in Pune


Announcement

To Advertise in our website please e-mail us at advertisement@equitybulls.com
Companies can send their Press Releases to pressrelease@equitybulls.com

Links

  • Home
  • Contact
  • Our Team

Contact

The website is developed and maintained by Chennai Scripts
C-4, Podhigai Flats, Pillayar Koil Street, Nesapakkam
Chennai
Tamil Nadu
India
600078
E-mail: chennaiscripts@gmail.com
Mobile Phone Number: +91-88776-69935
www.chennaiscripts.com

Website Created & Maintained by : Chennai Scripts
Nesapakkam, Chennai - 600 078,
Tamil Nadu, India

Disclaimer Copyright © - 2025